These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38050454)

  • 1. Impact of radioiodine therapy on recurrence and survival outcomes in intermediate-risk papillary thyroid carcinoma -A systematic review and meta-analysis.
    Chandekar KR; Satapathy S; Bal C
    Clin Endocrinol (Oxf); 2024 Feb; 100(2):181-191. PubMed ID: 38050454
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
    Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
    Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is Postoperative Adjuvant Radioactive Iodine Ablation Therapy Always Necessary for Intermediate-Risk Papillary Thyroid Cancer Patients With Central Neck Metastasis?
    Han K; Noh HM; Jeong HM; Lim YC
    Ann Surg Oncol; 2021 Nov; 28(12):7533-7544. PubMed ID: 34043093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term clinical outcomes and prognostic factors for patients with papillary thyroid carcinoma with other organ invasions after adjuvant radioactive iodine.
    Kawamoto T; Shikama N; Fukumori T; Hoshi M; Yamada T
    Endocrine; 2023 Apr; 80(1):79-85. PubMed ID: 36367673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer.
    Ruel E; Thomas S; Dinan M; Perkins JM; Roman SA; Sosa JA
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1529-36. PubMed ID: 25642591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma.
    Kruijff S; Aniss AM; Chen P; Sidhu SB; Delbridge LW; Robinson B; Clifton-Bligh RJ; Roach P; Gill AJ; Learoyd D; Sywak MS
    Surgery; 2013 Dec; 154(6):1337-44; discussion 1344-5. PubMed ID: 24383104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
    Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
    Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Radioactive Iodine Therapy on Cancer-Specific Survival of Papillary Thyroid Cancer Tall Cell Variant.
    Dai P; Zhao W; Zheng X; Luo H; Wang X
    J Clin Endocrinol Metab; 2024 Feb; 109(3):e1260-e1266. PubMed ID: 37804527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TIMING OF RADIOACTIVE IODINE THERAPY DOES NOT IMPACT OVERALL SURVIVAL IN HIGH-RISK PAPILLARY THYROID CARCINOMA.
    Suman P; Wang CH; Abadin SS; Block R; Raghavan V; Moo-Young TA; Prinz RA; Winchester DJ
    Endocr Pract; 2016 Jul; 22(7):822-31. PubMed ID: 27018620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
    Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
    Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RAI therapy in low-risk papillary thyroid cancer: recurrence reduction and long-term outcomes in the Turkish population.
    Bilgic S; Meral R; Sağer MS; Sönmezoğlu K
    BMC Cancer; 2024 Oct; 24(1):1273. PubMed ID: 39402494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The outcomes and prognostic factors of patients who underwent reoperation for persistent/recurrent papillary thyroid carcinoma.
    Sun W; Di L; Chen L; Li D; Wu Y; Xiang J; Zhou S; Sun T
    BMC Surg; 2022 Nov; 22(1):374. PubMed ID: 36324095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of delayed initial radioactive iodine therapy and clinical outcomes in papillary thyroid cancer: a two-center retrospective study.
    He T; Li M; Gao ZL; Li XY; Zhong HR; Ding CS; Cai HW
    Nucl Med Commun; 2024 Sep; 45(9):779-787. PubMed ID: 38832411
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of adjuvant radioactive iodine therapy after reoperation in papillary thyroid carcinoma with cervical lymph node recurrence.
    Zhang Y; Zhu X; Fan Q; Huang Q; Tu Y; Jiang L; Zhang Z; Chen J
    Jpn J Radiol; 2023 Oct; 41(10):1148-1156. PubMed ID: 37266825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Papillary Thyroid Microcarcinoma Presenting with Palpable Lateral Lymphadenopathy.
    Papachristos A; Do K; Tsang VH; Sywak M; Gill AJ; Sidhu S; Clifton-Bligh RJ; Glover A; Gild ML
    Thyroid; 2022 Sep; 32(9):1086-1093. PubMed ID: 35703333
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical impact of radioactive iodine dose selection based on the number of metastatic lymph nodes in patients with papillary thyroid carcinoma: A multicenter retrospective cohort study.
    Kwon SY; Kim MH; Kong E; Chong A; Yoo SW; Jeon S; Park SA; Kim DW; Kang SH; Choi JE; Ha JM; Jeong SY; Lee SW
    Clin Endocrinol (Oxf); 2021 Dec; 95(6):901-908. PubMed ID: 34185324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of Patients with an Intermediate-Risk Group According to the Japanese Risk Classification of Papillary Thyroid Carcinoma.
    Horiuchi K; Fujimoto M; Hidenori K; Yoshida Y; Noguchi E; Omi Y; Okamoto T
    World J Surg; 2023 Oct; 47(10):2464-2473. PubMed ID: 37266697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Microscopic positive margins in papillary thyroid cancer do not impact disease recurrence.
    Abraham E; Tran B; Roshan D; Graham S; Lehane C; Wykes J; Campbell P; Ebrahimi A
    ANZ J Surg; 2018 Nov; 88(11):1193-1197. PubMed ID: 29701284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radioiodine versus no radioiodine outcomes in low-risk differentiated thyroid cancers: A propensity-score matched analysis.
    Satapathy S; Tupalli A; Chandekar KR; Ballal S; Bal C
    Clin Endocrinol (Oxf); 2023 Nov; 99(5):483-491. PubMed ID: 37491776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.